National Cancer Institute; Amended Notice of Meeting, 75888-75889 [2011-31149]
Download as PDF
<![CDATA[
75888
Federal Register / Vol. 76, No. 233 / Monday, December 5, 2011 / Notices
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: AIDS Research
Advisory Committee, NIAID, AIDS Vaccine
Research Subcommittee.
Date: January 31–February 1, 2012.
Time: 8:30 a.m. to 5 p.m.
Agenda: The AVRS will meet with the
NIAID-sponsored Strategic Working Group
(SWG). Presentations and discussion of
current and future plans of the HIV Vaccine
Trials Network (HVTN).
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: James A. Bradac, Ph.D.,
Program Official, Preclinical Research and
Development Branch, Division of AIDS,
Room 5116, National Institutes of Health/
NIAID, 6700B Rockledge Drive, Bethesda,
MD 20892–7628, (301) 435–3754,
jbradac@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–31154 Filed 12–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jlentini on DSK4TPTVN1PROD with NOTICES
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
VerDate Mar<15>2010
16:52 Dec 02, 2011
Jkt 226001
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering; NACBIB January 2012.
Date: January 20, 2012.
Open: 9 a.m. to 1 p.m.
Agenda: Report from the Institute Director,
other Institute Staff and presentation of
working group reports.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Independence Room,
2nd Level, Bethesda, MD 20817.
Closed: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Independence Room,
2nd Level, Bethesda, MD 20817.
Contact Person: Anthony Demsey, Ph.D.,
Director, National Institute of Biomedical
Imaging and Bioengineering, 6707
Democracy Boulevard, Room 241, Bethesda,
MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
additional information for the meeting will
be posted when available.
Dated: November 29, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–31157 Filed 12–2–11; 8:45 am]
BILLING CODE 4140–01–P
notify the Contact Person listed below
in advance of themeeting.
Name of Committee: AIDS Research
Advisory Committee, NIAID.
Date: January 30, 2012.
Time: 1 p.m. to 5 p.m.
Agenda: Reports from the Division Director
and other staff.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Contact Person: Rona L. Siskind, Executive
Secretary, AIDS Research Advisory
Committee, Division of AIDS, NIAID/NIH,
6700B Rockledge Drive, Room 4139,
Bethesda, MD 20892–7601, (301) 435–3732.
Name of Committee: AIDS Research
Advisory Committee, NIAID.
Date: May 14, 2012.
Time: 1 p.m. to 5 p.m.
Agenda: Reports from the Division Director
and other staff.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Contact Person: Rona L. Siskind, Executive
Secretary, AIDS Research Advisory
Committee, Division of AIDS, NIAID/NIH,
6700B Rockledge Drive, Room 4139,
Bethesda, MD 20892–7601, (301) 435–3732.
Name of Committee: AIDS Research
Advisory Committee, NIAID.
Date: September 24, 2012.
Time: 1 p.m. to 5 p.m.
Agenda: Reports from the Division Director
and other staff.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive,
Conference Rooms E1/E2, Bethesda, MD
20892.
Contact Person: Rona L. Siskind, Executive
Secretary AIDS Research Advisory
Committee, Division of AIDS, NIAID/NIH,
6700B Rockledge Drive, Room 4139,
Bethesda, MD 20892–7601, (301) 435–3732.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2011–31155 Filed 12–2–11; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of
Meetings
BILLING CODE 4140–01–P
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the AIDS
Research Advisory Committee, NIAID.
The meetings will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, December 5, 2011,
6:30 p.m. to December 6, 2011, 5 p.m.,
National Institutes of Health, Building
E:\FR\FM\05DEN1.SGM
05DEN1
Federal Register / Vol. 76, No. 233 / Monday, December 5, 2011 / Notices
31, 31 Center Drive, Conference Room
10, Bethesda, MD 20892 which was
published in the Federal Register on
October 27, 2011, 76 FR 66733.
This Notice is amending the start and
end times of the closed session from
3:30 p.m.–5 p.m. to 4:20 p.m.–5:15 p.m.
The end time of the meeting has also
changed from 5 p.m. to 5:15 p.m. The
meeting is partially closed to the public.
Dated: November 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–31149 Filed 12–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
jlentini on DSK4TPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:52 Dec 02, 2011
Jkt 226001
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; (240) 276–
2600 (voice), (240) 276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires {or set}
strict standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
FOR FURTHER INFORMATION CONTACT:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories:
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, (414)
328–7840/(800) 877–7016, (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
(585) 429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, (901) 794–5770/(888) 290–
1150.
Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, (615) 255–
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
75889
2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.).
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, (504) 361–
8989/(800) 433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, (804) 378–9130, Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, (501) 202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, (800)
445–6917.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, (229) 671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
(215) 674–9310.
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, (662)
236–2609.
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, (519)
679–1630.
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, (713) 856–8288/
(800) 800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, (908) 526–2400/(800) 437–
4986, (Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
(919) 572–6900/(800) 833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, (866) 827–
8042/(800) 233–6339, (Formerly:
LabCorp Occupational Testing
Services, Inc.; MedExpress/National
Laboratory Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, (913) 888–3927/(800) 873–
8845, (Formerly: Quest Diagnostics
E:\FR\FM\05DEN1.SGM
05DEN1
]]>Agencies
[Federal Register Volume 76, Number 233 (Monday, December 5, 2011)]
[Notices]
[Pages 75888-75889]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31149]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Advisory Board, December 5, 2011, 6:30 p.m. to December 6, 2011,
5 p.m., National Institutes of Health, Building
[[Page 75889]]
31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892 which was
published in the Federal Register on October 27, 2011, 76 FR 66733.
This Notice is amending the start and end times of the closed
session from 3:30 p.m.-5 p.m. to 4:20 p.m.-5:15 p.m. The end time of
the meeting has also changed from 5 p.m. to 5:15 p.m. The meeting is
partially closed to the public.
Dated: November 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-31149 Filed 12-2-11; 8:45 am]
BILLING CODE 4140-01-P
